Despite data indicating that patients suffering from non-small cell lung cancer with EGFR mutations might benefit from first-line therapy with gefitinib, several unresolved issues make it difficult to judge its final clinical value. Phase III studies were conducted in a population not representative for a Caucasian population and challenges remain in the determination of EGFR status.